Skip to main content
. 2017 May 30;8(56):95083–95094. doi: 10.18632/oncotarget.18297

Table 2. Association between the quantity of each immune subset and progression-free survival.

Factors Hazard ratio* 95% CI p-value
Suppressor cells Granulocytic MDSCs 2.61 1.20–5.68 0.01
Monocytic MDSCs 0.88 0.43–1.82 0.73
CD4+FOXP3+ 0.64 0.32–1.26 0.19
Naïve Tregs 1.00 0.51–1.97 0.99
Effector Tregs 1.01 0.51–2.00 0.98
Effector cells CD3+ 0.79 0.39–1.57 0.49
CD4+ 1.03 0.52–2.04 0.93
 Naïve 0.78 0.39–1.56 0.48
 Central memory 1.56 0.79–3.07 0.20
 Effector memory 0.87 0.44–1.72 0.69
 Terminally differentiated effector 0.62 0.31–1.23 0.17
 Granzyme B+ 1.14 0.57–2.27 0.71
 Perforin+ 0.99 0.50–1.96 0.99
 Ki67+ 1.11 0.56–2.18 0.77
CD8+ 0.80 0.40–1.59 0.52
 Naïve 1.20 0.61–2.36 0.61
 Central memory 0.74 0.38–1.46 0.39
 Effector memory 0.65 0.33–1.28 0.21
 Terminally differentiated effector 0.65 0.33–1.29 0.21
 Granzyme B+ 0.75 0.38–1.49 0.41
 Perforin+ 0.85 0.43–1.68 0.65
 Ki67+ 0.98 0.50–1.95 0.96
Natural killer 0.78 0.39–1.53 0.47
Antigen presenting cells Myeloid dendritic cells 0.98 0.47–2.04 0.96
Plasmacytoid dendritic cells 0.83 0.40–1.71 0.61

MDSCs, myeloid-derived suppressor cells; Tregs, regulatory T cells.

* Low group (< median) in each immune subset was used as a reference.